Cytosine arabinoside (Ara‐C) plus alpha‐interferon (αIFN) determine prolonged complete remissions in patients with aggressive non‐Hodgkin's lymphoma partially responsive to first‐line doxorubicin‐containing regimens

Authors:

Abstract
Summary. Ten patients with aggressive NHL who failed to achieve a complete remission with first‐line chemotherapy were treated with Ara‐C and αIFN. Ara‐C was administered subcutaneously at 100mg on day 1, 150mg on day 2 and 200 mg on days 3,4 and 5 of a 28 d cycle; αIFN was given at 3 million International Units three times a week and continued for 2 years in CR patients. Six CR were attained with a median duration of 36+ months. Toxicity was mild. A new approach to second‐line therapy for aggressive NHL is proposed.

This publication has 9 references indexed in Scilit: